ANAB
Price
$51.59
Change
+$0.23 (+0.45%)
Updated
Jun 9, 12:13 PM (EDT)
Capitalization
1.5B
62 days until earnings call
Intraday BUY SELL Signals
ENTA
Price
$11.25
Change
+$0.18 (+1.63%)
Updated
Jun 9, 12:16 PM (EDT)
Capitalization
322.48M
62 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANAB vs ENTA

Header iconANAB vs ENTA Comparison
Open Charts ANAB vs ENTABanner chart's image
ANAB vs ENTA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ANAB vs. ENTA commentary
Jun 09, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANAB is a Hold and ENTA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2026
Stock price -- (ANAB: $51.38 vs. ENTA: $11.09)
Brand notoriety: ANAB and ENTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANAB: 55% vs. ENTA: 89%
Market capitalization -- ANAB: $1.5B vs. ENTA: $322.48M
ANAB [@Biotechnology] is valued at $1.5B. ENTA’s [@Biotechnology] market capitalization is $322.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $112.43B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANAB’s FA Score shows that 1 FA rating(s) are green whileENTA’s FA Score has 1 green FA rating(s).

  • ANAB’s FA Score: 1 green, 4 red.
  • ENTA’s FA Score: 1 green, 4 red.
According to our system of comparison, ANAB is a better buy in the long-term than ENTA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANAB’s TA Score shows that 4 TA indicator(s) are bullish while ENTA’s TA Score has 4 bullish TA indicator(s).

  • ANAB’s TA Score: 4 bullish, 6 bearish.
  • ENTA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both ANAB and ENTA are a bad buy in the short-term.

Price Growth

ANAB (@Biotechnology) experienced а -3.32% price change this week, while ENTA (@Biotechnology) price change was -12.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.55%. For the same industry, the average monthly price growth was -8.04%, and the average quarterly price growth was -5.11%.

Reported Earning Dates

ANAB is expected to report earnings on Aug 10, 2026.

ENTA is expected to report earnings on Aug 10, 2026.

Industries' Descriptions

@Biotechnology (-4.55% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANAB($1.5B) has a higher market cap than ENTA($322M). ANAB YTD gains are higher at: 58.981 vs. ENTA (-29.677). ANAB has higher annual earnings (EBITDA): 58.5M vs. ENTA (-46.56M). ANAB has more cash in the bank: 286M vs. ENTA (164M). ANAB has less debt than ENTA: ANAB (13.6M) vs ENTA (56.5M). ANAB has higher revenues than ENTA: ANAB (232M) vs ENTA (69.2M).
ANABENTAANAB / ENTA
Capitalization1.5B322M464%
EBITDA58.5M-46.56M-126%
Gain YTD58.981-29.677-199%
P/E RatioN/AN/A-
Revenue232M69.2M335%
Total Cash286M164M174%
Total Debt13.6M56.5M24%
FUNDAMENTALS RATINGS
ANAB vs ENTA: Fundamental Ratings
ANAB
ENTA
OUTLOOK RATING
1..100
5154
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
26100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
3763
P/E GROWTH RATING
1..100
701
SEASONALITY SCORE
1..100
31n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ANAB's Valuation (94) in the Biotechnology industry is in the same range as ENTA (99). This means that ANAB’s stock grew similarly to ENTA’s over the last 12 months.

ANAB's Profit vs Risk Rating (26) in the Biotechnology industry is significantly better than the same rating for ENTA (100). This means that ANAB’s stock grew significantly faster than ENTA’s over the last 12 months.

ANAB's SMR Rating (99) in the Biotechnology industry is in the same range as ENTA (99). This means that ANAB’s stock grew similarly to ENTA’s over the last 12 months.

ANAB's Price Growth Rating (37) in the Biotechnology industry is in the same range as ENTA (63). This means that ANAB’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for ANAB (70). This means that ENTA’s stock grew significantly faster than ANAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANABENTA
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
69%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
77%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 20 days ago
81%
Bullish Trend 19 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
79%
Bearish Trend 1 day ago
83%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
69%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ANAB
Daily Signal:
Gain/Loss:
ENTA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSSIX42.93N/A
N/A
Goldman Sachs Small Cap Value Inst
IGFAX8.32N/A
N/A
VY® Morgan Stanley Global Franchise A
BRSYX16.32N/A
N/A
MFS Blended Research Small Cap Eq R6
RIVJX20.73N/A
N/A
American Funds International Vntg R-5E
ACSHX33.48N/A
N/A
Invesco Comstock R5

ANAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANAB has been loosely correlated with XNCR. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ANAB jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANAB
1D Price
Change %
ANAB100%
+2.00%
XNCR - ANAB
40%
Loosely correlated
-3.10%
CLRB - ANAB
40%
Loosely correlated
-1.93%
QTTB - ANAB
38%
Loosely correlated
-8.24%
AMRN - ANAB
38%
Loosely correlated
+1.94%
VIR - ANAB
36%
Loosely correlated
-2.31%
More

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with ORKA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then ORKA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
-1.68%
ORKA - ENTA
41%
Loosely correlated
+6.53%
DWTX - ENTA
39%
Loosely correlated
-2.67%
CNTN - ENTA
36%
Loosely correlated
+15.65%
BCAX - ENTA
35%
Loosely correlated
+0.50%
ANAB - ENTA
34%
Loosely correlated
+2.00%
More